Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 2,578 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $47.83, for a total transaction of $123,305.74. Following the completion of the transaction, the chief executive officer now directly owns 217,566 shares in the company, valued at $10,406,181.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Steven Leonard Chapman also recently made the following trade(s):
- On Wednesday, June 28th, Steven Leonard Chapman sold 2,605 shares of Natera stock. The shares were sold at an average price of $50.88, for a total transaction of $132,542.40.
Natera Stock Performance
Shares of NTRA stock opened at $46.79 on Tuesday. The company has a market capitalization of $5.35 billion, a price-to-earnings ratio of -8.75 and a beta of 1.22. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.74 and a current ratio of 3.88. The company has a 50-day simple moving average of $49.53 and a 200 day simple moving average of $49.59. Natera, Inc. has a 52 week low of $34.00 and a 52 week high of $59.75.
Institutional Trading of Natera
Institutional investors have recently bought and sold shares of the business. Machina Capital S.A.S. bought a new stake in Natera in the 1st quarter valued at about $28,000. Harbor Capital Advisors Inc. bought a new stake in shares of Natera during the 2nd quarter worth approximately $30,000. Belpointe Asset Management LLC bought a new stake in shares of Natera during the 4th quarter worth approximately $28,000. OLD Mission Capital LLC bought a new stake in shares of Natera during the 4th quarter worth approximately $36,000. Finally, Quent Capital LLC lifted its holdings in shares of Natera by 1,234.6% during the 2nd quarter. Quent Capital LLC now owns 1,081 shares of the medical research company’s stock worth $53,000 after acquiring an additional 1,000 shares during the period. Institutional investors own 92.18% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on NTRA shares. UBS Group started coverage on shares of Natera in a research report on Friday, May 5th. They set a “buy” rating and a $76.00 price target on the stock. The Goldman Sachs Group cut their price objective on shares of Natera from $70.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday. Credit Suisse Group boosted their price objective on shares of Natera from $65.00 to $70.00 in a research report on Wednesday, May 10th. StockNews.com assumed coverage on shares of Natera in a research report on Thursday, May 18th. They issued a “sell” rating on the stock. Finally, Piper Sandler cut their price objective on shares of Natera from $80.00 to $70.00 in a research report on Tuesday, May 30th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.40.
About Natera
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Articles
- Five stocks we like better than Natera
- Manufacturing Stocks Investing
- 3 Housing Stocks to Avoid as Interest Rates Rise
- How to Invest in Esports
- AMC: Is a Big Squeeze in the Coming Attractions?
- The “How” and “Why” of Investing in 5G Stocks
- Rivian: A Roaring Rise Or Time To Cash Out?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
